Quaife, Samantha L.
Vrinten, Charlotte
Ruparel, Mamta
Janes, Samuel M.
Beeken, Rebecca J.
Waller, Jo
McEwen, Andy
Funding for this research was provided by:
Medical Research Council (MR/K501268/1)
Cancer Research UK (C1418/A14134)
Wellcome Trust (WT091730MA)
Article History
Received: 23 March 2017
Accepted: 24 April 2018
First Online: 2 May 2018
Ethics approval and consent to participate
: This study was exempt from ethical approval by the UCL Research Ethics Committee because it used anonymous and non-sensitive survey methods with participants who did not comprise a vulnerable group.
: SLQ, CV, MR, SMJ, RJB and JW have no competing interests to declare. AM has received travel funding, honorariums and consultancy payments from manufacturers of smoking cessation products (Pfizer Ltd., Novartis UK and GSK Consumer Healthcare Ltd) and hospitality from North51 who provide online and database services. AM also receives payment for providing training to smoking cessation specialists; receives royalties from books on smoking cessation and has a share in a patent of a nicotine delivery device. AM is an Associate of the New Nicotine Alliance (NNA) that works to foster greater understanding of safer nicotine products and technologies.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.